Creative Planning Boosts Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Creative Planning increased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 7.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 50,371 shares of the medical instruments supplier’s stock after acquiring an additional 3,526 shares during the period. Creative Planning owned about 0.07% of West Pharmaceutical Services worth $15,119,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new position in shares of West Pharmaceutical Services in the 1st quarter worth $27,000. Crewe Advisors LLC boosted its position in West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at about $40,000. ORG Partners LLC increased its position in shares of West Pharmaceutical Services by 820.0% during the 1st quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 123 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in shares of West Pharmaceutical Services by 5,633.3% in the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 169 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Performance

WST opened at $287.25 on Tuesday. The company’s 50 day moving average is $299.96 and its 200 day moving average is $324.52. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The company has a market cap of $20.84 billion, a price-to-earnings ratio of 40.86, a PEG ratio of 10.46 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12-month low of $265.00 and a 12-month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue was down 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.11 EPS. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.53% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.